Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-05-01
2007-05-01
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S577000
Reexamination Certificate
active
10121481
ABSTRACT:
The invention provides methods for modulating an immune response in a subject including, for example, administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor sufficient to modulate the immune response. In one aspect, the lymphocyte differentiation factor comprises protein A (PA).
REFERENCES:
patent: 4617266 (1986-10-01), Fahnestock
patent: 5084398 (1992-01-01), Huston et al.
patent: 5091091 (1992-02-01), Terman
patent: 5422427 (1995-06-01), Russell
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5965400 (1999-10-01), Briles
patent: 6312944 (2001-11-01), Russell
patent: 6447777 (2002-09-01), Terman et al.
patent: 91/19509 (1991-12-01), None
patent: 97/36614 (1997-10-01), None
patent: 00/69457 (2000-11-01), None
Feldman et al ., Transplant. Proc. 1998, 30, 4126-4127.
Cochlovius et al Modern Drug Discovery, 2003, pp. 33-38.
Van Noort et al. International Review of Cytology, 1998, v. 178, pp. 127-130.
Mestas et al ., J. of Immunology, 2004, 172, pp. 271-238.
Webster Dictionary, 1984, Houghton, Mifflin Company, p. 1013.
William Paul., Fundamental Immunology, 1998, Lippincott-Raven Publisher, pp. 788, 1105.
Sinha et al., Immunology Letters, 1999, v. 67, pp. 157-165.
Nardella, et al., “IgG Rheumatoid Factors and Staphylococcal Protein A Bind to A Common Molecular Site on IgG,”The Journal of Experimental Medicine, (Dec. 1, 1985), vol. 162, No. 6, pp. 1811-1824.
Silverman, et al., “In VivoConsquences of B Cell Superantigen Immunization”,Annals of the New York Academy of Sciences, (Apr. 5, 1997) vol. 815, pp. 105-110.
Friedman, et al., “Microbial Superantigens as Etiopathogenic Agents in Autoimmunity”,Controversies in Clinical Rheumatology, (Feb. 1993), vol. 19, No. 1, pp. 207-222.
Levinson, et al., “Staphylococcus aureusCowan I, Potent Stimulus of Immunoglobulin M Rheumatoid Factor Production”,Journal of Clinical Investigation, (Sep. 1986), vol. 78, No. 3, pp. 612-617.
Silverman, et al., “A B Cell Superantigen-induced Persisent “Hole” in the B-1 Repertoire”,Journal of Experimental Medicine, (Jul. 3, 2000), vol. 192, No. 1, pp. 87-98.
He, et al., “Selective Induction of Rheumatoid Factors by Superantigens and Human Helper T Cells”,Journal of Clinical Investigation, (Feb. 1992) vol. 89, pp. 673-680.
Mourad, et al., “Engagement of Major Histocompatibility Complex Class II Molecules by Superantigen Induces Inflammatory Cytokine Gene Expression in Human Rheumatoid Fibroblast-like Synoviocytes,”Journal of Experimental Medicine, (Feb. 1992), vol. 175, pp. 613-616.
Kozlowski, et al., “Staphylococcus aureusCowan I-Induced Human Immunoglobulin Responses: Preferential IgM Rheumatoid Factor Production and VH3 mRNA Expression by Protein A-Binding B Cells”,Journal of Clinical Immunology, (1995) vol. 15, No. 3, pp. 145-151.
Levinson, et al., “Prominent IgM Rheumatoid Factor Production by Human Cord Blood Lymphocytes Stimulated in Vitro WithStaphylococcus aureusCowan I”,Journal of Immunology, (Oct. 1, 1997), vol. 139, No. 7, pp. 2237-2241.
Matic et al.; Background and Indications for Protein A-Based Extracorporeal Immunoadsorption; Therapeutics Apheresis, vol. 5, No. 5; Oct. 2001; pp. 394-403.
Das et al.; Protein A-Activated Rat Splenic Lymphocyte Proliferation Involves Tyrosine Kinase-Phospholipase C-Protein Kinase C Patyway; Immunopharmacology and Immunotoxicology, vol. 22, No. 1, 2000; pp. 75-90.
Ghosh et al; Protection by Protein A of Apoptotic Cell Death Caused by Anti-AIDS Drug Zidovudine; Biochemical and Biophysical Research Communications, vol. 264, No. 2; 1999; pp. 601-604.
Benny et al.; Clinical Evaluation of a Staphylococcal Protein A Immunoadsorption System in the Treatment of Myasthenia Gravis Patients; Transfusion, vol. 39, No. 7; Jul. 1999; pp. 682-687.
Das et al.; Induction of Cell Proliferation and Apoptosis: Dependence on the Dose of the Inducer; Biochemical and Biophysical Research Communications, vol. 260, No. 1; 1999; pp. 105-110.
Levinson, et al., “IgM Rheumatoid Factor Produced in Response toS. aureusCowan I: Role of Protein A and Preferential Utilization of VH3 Heavy Chains”,The Journal of Immunology, (Apr. 15, 1993), vol. 150, No. 8, Part 2, Abstract #1355.
Kozlowski, et al., “In Vivo Inflammatory Response to a Prototypic B Cell Superantigen: Elicitation of an Arthus Reaction by Staphylococcal Protein A”,Journal of Immunology, (1998), vol. 160, pp. 5346-5252.
Silverman, et al., “B-Cell Superantigens: Molecular and Cellular Implications”,Intern. Rev. Immunol., (1997), vol. 14, pp. 259-290.
Rheumawire Dec. 7, 2001 (BR) New mechanism of action proposed for Prosorba column, http://ww.jointanbone.org
ews/200112
ews20011207a.cfm.
Goodyear, C., et al., 1462—Evidence of a novel immunomodulatory mechanism of action of Prosorba therapy: release of staphyloccoccal protein a induces VH region targeted apoptotic death of B lymphocytes, Merck's Rheumatology Young Investigator's Program (Nov. 2001), p. S296.
Sinha, P., et al., A Minimized Fc Binding Peptide from Protein A Induces Immunocyte Proliferation and Evokes Th1-Type Response in Mice, Biochemical and Biophysical Research Communications, 258:141-147 (1999).
Samtleben, W., et al., , Ex vivo and in vivo protein A perfusion: Background, basic investigations, and first clinical experiences, Blood Purification, vol. 5, pp. 179-192, (1987).
Schneider, M. et al., Immunoadsorption in systemic connective tissue diseases and primary vasculitis, Therapeutic Apheresis, vol. 1 (No. 2), pp. 117-120, (1997).
Felson, D., et al., The prosorba column for treatment of refractory rheumatoid arthritis, Arthritis & Rheumatism, vol. 42 (No. 10), pp. 2153-2159, (1999).
Caldwell, J., et al., A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis, J. Rheumatology, vol. 26, (No. 8), pp. 1657-1662, (1999).
Wiesenhutter, C.W. et al., Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: A pilot trial, J. Rheumatology, vol. 21 (No. 5), pp. 804-812, (1992).
Ghosh, A.K., et al.,S. aureusSuperantigen Protein A Expands CD4+/CD8+/CD19+/CD34+ Cells in Mice: A Potential Immunorestorer, Biochemical and Biophysical Research Communications, pp. 142-146, ((1999)).
Paliard, X., et al., Evidence for the Effects of a Superantigen in Rheumatoid Arthritis, Science, pp. 325-329, ((1991)).
Romagnani, S., et al., Surface Immunoglobulins are Involved in the Interaction of Protein A with Human B Cells and in the Triggering of B cell Proliferation Induced by Protein A-ContainingStaphylococcus aureus, The Journal of Immunology, pp. 1307-1313, ((1981)).
Catalona, W.J., et al., Lambda Inteferon Induced byS. aureusProtein A Augments Natural Killing and ADCC, Nature, 291:77-79 (1981).
Belyavskyi Michail A.
Chan Christina
Protalex, Inc.
LandOfFree
Protein A compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein A compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein A compositions and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3728800